Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Baxter
Express Scripts
Dow
Colorcon

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

PHENDIMETRAZINE TARTRATE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Phendimetrazine Tartrate patents expire, and what generic alternatives are available?

Phendimetrazine Tartrate is a drug marketed by Graham Dm, Virtus Pharms, Sandoz, Vitarine, Barr, Chartwell Rx, Elite Labs Inc, Ferndale Labs, Inwood Labs, Ivax Pharms, Ivax Sub Teva Pharms, Kv Pharm, Kvk Tech, Mfg Chemists, Mikart, Nexgen Pharma Inc, Numark, Pvt Form, Solvay, Upsher Smith Labs, Usl Pharma, and Watson Labs. and is included in sixty-five NDAs.

The generic ingredient in PHENDIMETRAZINE TARTRATE is phendimetrazine tartrate. There are five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.

Drug patent expirations by year for PHENDIMETRAZINE TARTRATE
Drug Prices for PHENDIMETRAZINE TARTRATE

See drug prices for PHENDIMETRAZINE TARTRATE

Pharmacology for PHENDIMETRAZINE TARTRATE
Synonyms for PHENDIMETRAZINE TARTRATE
(2R,3R)-2,3-bis(oxidanyl)butanedioic acid; (2S,3S)-3,4-dimethyl-2-phenyl-morpholine
(2R,3R)-2,3-dihydroxybutanedioic acid; (2S,3S)-3,4-dimethyl-2-phenylmorpholine
(2S,3S)-3,4-Dimethyl-2-phenylmorpholine L-(+)-tartrate (1:1)
21102-82-9
2233-26-3
238P764
50-58-8
6985IP0T80
A828189
AC1L3R57
AC1Q5R36
Adipost
ALPHAZINE
Bontril (TN)
BONTRIL PDM
CAM-METRAZINE
D-3,4-Dimethyl-2-phenyl-morpholine tartrate
D02080
DI-METREX
DTXSID70198165
EINECS 200-051-0
K631
LS-92795
MELFIAT
MELFIAT-105
Metra
Morpholine, 3,4-dimethyl-2-phenyl-, (+)-, tartrate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, (+)-, tartrate (1:1) (8CI)
Morpholine, 3,4-dimethyl-2-phenyl-, (2S-trans)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, (2S,3S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, tartrate, D-
PHENAZINE-35
Phendimetrazine hydrogen tartrate
Phendimetrazine tartrate (USP)
Phendimetrazine tartrate [USAN]
Phendimetrazine tartrate [USP]
phendimetrazine tartrate, (2S-trans(R-(R*,R*)))-isomer
Prelu 2
Prelu-2
SCHEMBL160375
Sodium alginate, viscosity ~100mp.s
SPRX
SPRX-105
SPRX-3
Statobex
STATOBEX-G
UNII-6985IP0T80
X-TROZINE L.A
X-trozine L.A.

US Patents and Regulatory Information for PHENDIMETRAZINE TARTRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kv Pharm PHENDIMETRAZINE TARTRATE phendimetrazine tartrate TABLET;ORAL 085525-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Inwood Labs PHENDIMETRAZINE TARTRATE phendimetrazine tartrate TABLET;ORAL 084740-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Sandoz PHENDIMETRAZINE TARTRATE phendimetrazine tartrate TABLET;ORAL 085402-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Vitarine PHENDIMETRAZINE TARTRATE phendimetrazine tartrate TABLET;ORAL 086005-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Nexgen Pharma Inc PHENDIMETRAZINE TARTRATE phendimetrazine tartrate TABLET;ORAL 086020-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Sandoz PHENDIMETRAZINE TARTRATE phendimetrazine tartrate TABLET;ORAL 085830-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Usl Pharma PHENDIMETRAZINE TARTRATE phendimetrazine tartrate TABLET;ORAL 084398-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Boehringer Ingelheim
McKinsey
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.